Systematic investing: decoding the value of analyst price targets
Systematic investing: decoding the value of analyst price targets
About this video
Jason Hall of Hamilton12 underscores the need to focus on financial analysts who conflict with systematic investing market trends. He underlines the importance of fresh, unbiased research from consistent and diligent analysts.
Jason delineates that investors should home in on promptly updated analyst research suggestive of probable market shifts. Pointing out sectors where there have been enormous price movements and analysts' disagreement, which might signify overreactions to updates, Jason draws on examples from healthcare and technology sectors.
He firmly suggests investors heed the freshest relevant data. In his concluding remarks, Jason implies that the price targets posited by analysts offer significant investment worth for a brief time following the release of the research, which implies strategies for investment based on regular portfolio rebalancing in accordance with the latest information.
Find the full unedited transcript of this interview below:
0:00
Well in the world of systematic investing analyst price target services signal for investors looking for value. My next guest thinks that analysts that disagree with the market are worth paying attention to. Jason Hall from Hamilton 12 joins us now. Jason, good to see you. So why should we be looking to those who are who are disagreeing and I guess trying to disrupt the norm?
0:22
Well, Juliet, we know a lot about analysts research from
0:26
academic evidence that has being collated over the past 20 years. And analysts produce a couple of key quantitative outputs. One is the target price. One is an earnings per share forecast and one is a buy hold or sell recommendation. And they do a whole lot of work that underpins those key quantitative outputs. But investors have this vast array of research available to them, and they need a mechanism to work out what's quality research and what's not going to have timely investment value. And what we know about analyst research is that it is valuable provided it meets the following criteria. It's got to be recent. It's got to be timely because information becomes stale very quickly. And it has to be compiled by analysts who are unbiased and are quite diligent and sophisticated in their approach.
1:17
Um, and so one way you can ensure that you're looking at research which is diligent and sophisticated and timely is to look at analyst research that has been revised promptly in response to information that, you know is going to hit the market and be new. And we just had a period of
1:37
a lot of information coming to the market. We've had our usual fiscal year end reporting season. We're a vast amount of information hits the market at one time.
1:46
Some analysts are timely in response to their revisions of their earnings forecasts and their price targets. And some analysts are slow to update that information.
1:56
Um, if you want to identify analysts and information in those reports that are going to be high quality investment signals, you can compile the subset of information of analysts that just updated their information just before the end of the financial year and very shortly after earnings are released, updated that information and you can say, well, that's where analysts have got the most timely value relevant information for decision making, and that allows you to do the following thing. It allows you to identify when analysts substantially disagree with the share market reaction to the earnings that has been released. All right. Well, you've done some deep dive research into this as well, compiling individual analyst price targets in fiscal 2024 earnings per share forecast. So how more broadly can we identify some of these target price signals of disagreement?
2:51
Well, some sectors in the latest earnings announcement period has big price moves, and some of those sectors had small price moves. But of the sectors that had large price moves, there are four of them in which analysts said, well, hang on a minute, this appears to be an overreaction to whatever news came about.
3:13
On this chart, you can see on the horizontal axis, you've got the change in the share price from the 30th of June until the September 18th kind of end of the reporting season. And you can see, for example, energy and telecommunications had large share price increases over that two and a half month period of about 7 or 8%. And on the left hand side, you've got healthcare, consumer total consumer staples and tech stocks that had substantial share price falls. So bad news hit the market on the vertical axis. You've got the analyst response to the same information in terms of how they changed their target prices. And so all of these industries that are plotting above and to the left of that
3:58
45 degree line, that's where analysts are more optimistic than the market. That's where the analysts are saying, well, think I disagree. And in the bottom right, you've got analysts saying, I think this is an overreaction. I think share prices have gone up by a lot, but it's not justified by the new information which hit the market. So specifically, take healthcare. Healthcare in aggregate on a market value weighted basis was down almost 10%. Ramsay Healthcare was down. ResMed was down about 30% over that two and a half month period. But analysts target price is only came down by 2%. So analysts are saying, well, hang on a second, this is an overreaction. There was some bad news. But we really think that on a fundamental basis, this sector's only worth 2% less than it was two and a half months ago. So what are some Jason, sorry, what are some of the stock specific divergences? I note that you've given us an interesting chart on that too. In terms of the disagreement
4:57
between what we're seeing with analysts in the market.
5:01
Well, what I want to do is look at some stocks that analysts, you know, like investors in all likelihood, are going to be interested in. So I looked at the subset of stocks
5:11
that had substantial disagreement between equity analysts and the market
5:18
and which have large market cap, more than $2 billion and which pay fully franked dividends. And so these are stocks that form the backbone of lots of investors in Australia, especially people running self-managed super funds and their own portfolios. And so take in healthcare that we were just talking about, Sonic Healthcare was down almost around about 13% over this period. But analysts price targets, they're only down about 5%. So analysts are saying that this share market fall for sonic healthcare is an overreaction on the negative side by about 8%.
5:54
Another stock, which has had a substantial share price for Ventas services over that time period, 10% down. Analysts revise upwards their share prices by around about 2,325%. So analysts are saying the market's got this wrong. The market has
6:13
caused a correction in their stock substantially, but we've actually revised our share prices upwards. In contrast, on the right hand side, you've got big share price increases for companies like Beach Energy and other energy companies. Hub 24, TPG Telecom and Incitec Pivot. Analysts are saying, well, this is an overreaction. On the other side, analysts are more optimistic towards how 24 in telecom, but they've only revised up their target prices in the range of around 3 to 10%. So Beach Energy, their forecasts are unchanged. And for Incitec Pivot, their forecasts are down 5% compared to a share price increase of more than 10%.
6:58
So the key point is that within each sector there is this area of disagreement, which is what you want as an investor, but you have to identify well, which analysts are going to believe that disagree with the share market reaction? Yeah. So as you say, investors really benefit from looking at this data and the fact that there probably does need to be disagreement to at what point do you see analysts price targets as having real investment value?
7:25
While the research gives us a very clear indication of that, it has investment value for 1 to 2 months after the analyst research is released. So researchers have tested this. They perform portfolios in response to target price changes of analysts, and they rebalance those portfolios on a monthly basis. And what they observe is that if you follow by stocks that have upwards revisions to their target prices and those target prices are substantially above share prices, and you sell the stocks that have downward revisions to their target prices to the point where target prices are below share price and you keep rebalancing that portfolio monthly. That portfolio is able to earn returns which do better than a benchmark portfolio. But in contrast, over periods of six months, that portfolio doesn't do any better than just holding a buy and hold benchmark portfolio. So after 1 or 2 months, the investment value of that research starts to atrophy
8:26
quite quickly. So this has an important implication for investors there looking at their Morningstar research or their broker research or analyst research from any other source. They really have to look at the date of that research and ensure that if it's more than one month or two months stale,
8:44
it's going to have lost its investment signal. And they're probably want to find some research which is more recent.
8:52
And just talking about sectors again, more broadly, what did you find between the health care and technology in terms of those being correlated and the pessimism towards telcos and energy?
9:04
Well, like we could draw a bit of a long bow and say, well, healthcare and technology, they're your, your growth companies and growth companies have not done very well over that two and a half month period. And we could say that in the other sectors, your telecommunications and your energy sectors, there more of your value based mature industries and they've done more better in that recent period. Um, but I'm reluctant to say like as a value versus growth dichotomy, I just think that there happens to be industry specific information that came out. There were some substantially negative news about earnings for healthcare and tech stocks and their prospects of the future. I don't necessarily think that there's like a technology and healthcare crossover there. It just happens to be the case that the market reacted negatively, the substantial degree. Analysts are looking at more of a long term fundamental basis and saying, well, I think this is overcooked.